Yes, aripiprazole (Abilify) can be started in autistic children for anger, specifically when the anger manifests as irritability with physical aggression and severe tantrums.
Aripiprazole is FDA-approved for treating irritability associated with autism spectrum disorder in children ages 6-17 years 1. This is one of only two medications with this specific FDA indication, making it a first-line pharmacological option when behavioral interventions alone are insufficient.
When to Consider Aripiprazole
The 2014 AACAP guidelines clearly state: "Pharmacotherapy may be offered to children with ASD when there is a specific target symptom or comorbid condition" 2. Irritability—which encompasses physical aggression, severe tantrum behavior, and self-injurious behavior—is an appropriate target symptom 2.
Before initiating medication:
- Ensure the "anger" truly represents irritability with aggression/tantrums rather than anxiety, sensory overload, or communication frustration
- Rule out underlying medical causes (pain, constipation, sleep disturbance)
- Confirm that psychosocial interventions and behavioral strategies have been attempted or are being implemented concurrently
- Combining medication with parent training is moderately more efficacious than medication alone 2
Evidence for Efficacy
Multiple randomized controlled trials demonstrate aripiprazole's effectiveness:
- 56% positive response rate versus 35% on placebo in children ages 6-17 2
- Mean improvement of -6.17 points on the ABC-Irritability subscale (95% CI -9.07 to -3.26) 3
- Significant improvements also seen in hyperactivity and stereotypy subscales 2
- A 2026 meta-analysis confirmed these findings with mean difference of -5.18 on ABC-Irritability scores 4
Dosing Strategy
Start low and titrate slowly:
- Initial dose: 2 mg daily (studies used 5-15 mg/day flexibly dosed in children 6-17 years) 2
- Titrate based on response and tolerability
- Typical effective range: 5-15 mg/day 2
- Can be given once daily, with or without food 1
Critical Side Effects to Monitor
Weight gain is the most significant concern:
- Mean increase of 1.13 kg more than placebo over 8 weeks 3
- Monitor weight, BMI, and metabolic parameters (glucose, lipids) at baseline and regularly during treatment 1
Other common adverse effects:
- Sedation (RR 4.28 versus placebo) 3
- Increased appetite 2, 4
- Drooling, fatigue 2
- Tremor (RR 10.26 versus placebo) 3
- Extrapyramidal symptoms (generally less than older antipsychotics) 4, 5
Serious but rare risks (from FDA label):
- Neuroleptic malignant syndrome
- Tardive dyskinesia (may be irreversible)
- Metabolic syndrome
- Suicidal thoughts (black box warning for all antidepressants/antipsychotics in youth) 1
Reassessment and Duration
A critical but often overlooked point: After stabilization of irritability symptoms, periodic reassessment is essential to determine if ongoing treatment remains necessary 6. One discontinuation study found that relapse rates after stabilization did not significantly differ between continued aripiprazole versus placebo (hazard ratio 0.57,95% CI 0.28-1.12), suggesting that not all children require indefinite treatment 3.
The prescriber must:
- Reassess if the child doesn't respond as expected—consider whether the diagnosis was accurate, the dose/duration adequate, or adherence was poor 6
- Distinguish between medication-responsive biological symptoms versus behavioral reactions to psychosocial stressors 6
- Avoid the trap of using medication to address "all" symptoms when psychosocial interventions may be more appropriate 6
Common Pitfalls to Avoid
Using aripiprazole as first-line without behavioral interventions: Medication should facilitate engagement with educational and behavioral therapies, not replace them 2
Inadequate trial before declaring "non-response": Ensure adequate dose and duration (typically 6-8 weeks at therapeutic dose) before switching medications 6
Neglecting metabolic monitoring: Weight gain and metabolic effects are frequent and require proactive monitoring 4, 7
Continuing indefinitely without reassessment: After 6-12 months of stability, consider whether ongoing treatment is still needed 3
Misattributing all behavioral problems to ASD: Irritability may reflect untreated anxiety, depression, ADHD, or environmental stressors that require different approaches 6, 8